Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update

J. A. Johnson; K. E. Caudle; L. Gong; M. Whirl-Carrillo; C. M. Stein; S. A. Scott; M. T. Lee; B. F. Gage; S. E. Kimmel; M. A. Perera; J. L. Anderson; M. Pirmohamed; T. E. Klein; N. A. Limdi; L. H. Cavallari; M. Wadelius

doi:10.1002/cpt.668

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update

J. A. Johnson^*, K. E. Caudle, L. Gong, M. Whirl-Carrillo, C. M. Stein, S. A. Scott, M. T. Lee, B. F. Gage, S. E. Kimmel, M. A. Perera, J. L. Anderson, M. Pirmohamed, T. E. Klein, N. A. Limdi, L. H. Cavallari, M. Wadelius

^*Corresponding author for this work

Pharmacology

Research output: Contribution to journal › Article › peer-review

496 Scopus citations

Abstract

This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing. Evidence from the published literature is presented for CYP2C9, VKORC1, CYP4F2, and rs12777823 genotype-guided warfarin dosing to achieve a target international normalized ratio of 2–3 when clinical genotype results are available. In addition, this updated guideline incorporates recommendations for adult and pediatric patients that are specific to continental ancestry.

Original language	English (US)
Pages (from-to)	397-404
Number of pages	8
Journal	Clinical pharmacology and therapeutics
Volume	102
Issue number	3
DOIs	https://doi.org/10.1002/cpt.668
State	Published - Sep 2017

Funding

This work was funded by the National Institutes of Health (NIH) for CPIC (R24GM115264) and PharmGKB (R24GM61374). Relevant funding for other authors includes: NIH grants U01 GM074492 and U01 HG 007269 (JAJ), K23GM104401 (SAS), GM109145 (CMS), R01HL092173 and K24HL133373 (NAL), R01 HL097036 (BFG) and grants from the Swedish Research Council (Medicine 521-2011-2440 and 521-2014-3370), the Swedish Heart and Lung Foundation (20120557 and 20140291), and the Thuréus' Foundation (MW), the UK Department of Health and Medical Research Council (MP), and the EU FP7 programme for funding EU-PACT (MP, MW).

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1002/cpt.668

Cite this

Johnson, J. A., Caudle, K. E., Gong, L., Whirl-Carrillo, M., Stein, C. M., Scott, S. A., Lee, M. T., Gage, B. F., Kimmel, S. E., Perera, M. A., Anderson, J. L., Pirmohamed, M., Klein, T. E., Limdi, N. A., Cavallari, L. H., & Wadelius, M. (2017). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clinical pharmacology and therapeutics, 102(3), 397-404. https://doi.org/10.1002/cpt.668

@article{a5ee7195c86949b6be0c2ed7fd98ab7b,

title = "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update",

abstract = "This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing. Evidence from the published literature is presented for CYP2C9, VKORC1, CYP4F2, and rs12777823 genotype-guided warfarin dosing to achieve a target international normalized ratio of 2–3 when clinical genotype results are available. In addition, this updated guideline incorporates recommendations for adult and pediatric patients that are specific to continental ancestry.",

author = "Johnson, {J. A.} and Caudle, {K. E.} and L. Gong and M. Whirl-Carrillo and Stein, {C. M.} and Scott, {S. A.} and Lee, {M. T.} and Gage, {B. F.} and Kimmel, {S. E.} and Perera, {M. A.} and Anderson, {J. L.} and M. Pirmohamed and Klein, {T. E.} and Limdi, {N. A.} and Cavallari, {L. H.} and M. Wadelius",

note = "Publisher Copyright: {\textcopyright} 2017 American Society for Clinical Pharmacology and Therapeutics",

year = "2017",

month = sep,

doi = "10.1002/cpt.668",

language = "English (US)",

volume = "102",

pages = "397--404",

journal = "Clinical pharmacology and therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

number = "3",

}

Johnson, JA, Caudle, KE, Gong, L, Whirl-Carrillo, M, Stein, CM, Scott, SA, Lee, MT, Gage, BF, Kimmel, SE, Perera, MA, Anderson, JL, Pirmohamed, M, Klein, TE, Limdi, NA, Cavallari, LH & Wadelius, M 2017, 'Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update', Clinical pharmacology and therapeutics, vol. 102, no. 3, pp. 397-404. https://doi.org/10.1002/cpt.668

TY - JOUR

T1 - Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing

T2 - 2017 Update

AU - Johnson, J. A.

AU - Caudle, K. E.

AU - Gong, L.

AU - Whirl-Carrillo, M.

AU - Stein, C. M.

AU - Scott, S. A.

AU - Lee, M. T.

AU - Gage, B. F.

AU - Kimmel, S. E.

AU - Perera, M. A.

AU - Anderson, J. L.

AU - Pirmohamed, M.

AU - Klein, T. E.

AU - Limdi, N. A.

AU - Cavallari, L. H.

AU - Wadelius, M.

PY - 2017/9

Y1 - 2017/9

N2 - This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing. Evidence from the published literature is presented for CYP2C9, VKORC1, CYP4F2, and rs12777823 genotype-guided warfarin dosing to achieve a target international normalized ratio of 2–3 when clinical genotype results are available. In addition, this updated guideline incorporates recommendations for adult and pediatric patients that are specific to continental ancestry.

AB - This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing. Evidence from the published literature is presented for CYP2C9, VKORC1, CYP4F2, and rs12777823 genotype-guided warfarin dosing to achieve a target international normalized ratio of 2–3 when clinical genotype results are available. In addition, this updated guideline incorporates recommendations for adult and pediatric patients that are specific to continental ancestry.

UR - http://www.scopus.com/inward/record.url?scp=85017458868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017458868&partnerID=8YFLogxK

U2 - 10.1002/cpt.668

DO - 10.1002/cpt.668

M3 - Article

C2 - 28198005

AN - SCOPUS:85017458868

SN - 0009-9236

VL - 102

SP - 397

EP - 404

JO - Clinical pharmacology and therapeutics

JF - Clinical pharmacology and therapeutics

IS - 3

ER -

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update

Abstract

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this